With 6.19 million shares changed hands, the volume of the stock remained heavier than its average volume of 5.36 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $103.595 whereas the lowest price it dropped to was $102.32. The 52-week range on BSX shows that it touched its highest point at $104.25 and its lowest point at $62.63 during that stretch. It currently has a 1-year price target of $104.89. Beta for the stock currently stands at 0.81.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BSX was up-trending over the past week, with a rise of 0.41%, but this was up by 14.14% over a month. Three-month performance surged to 21.05% while six-month performance rose 38.55%. The stock gained 66.66% in the past year, while it has gained 14.60% so far this year. A look at the trailing 12-month EPS for BSX yields 1.21 with Next year EPS estimates of 2.81. For the next quarter, that number is 0.66. This implies an EPS growth rate of 20.27% for this year and 14.05% for next year. EPS is expected to grow by 16.02% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -2.05%.
Float and Shares Shorts:
At present, 1.47 billion BSX shares are outstanding with a float of 1.47 billion shares on hand for trading. On 2025-01-15, short shares totaled 14.4 million, which was 98.0 higher than short shares on 1734048000. In addition to Mr. Michael F. Mahoney as the firm’s Chairman, President & CEO, Mr. Daniel J. Brennan CPA serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.92224 of BSX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BSX reported revenue of $4209000000.0 and operating income of $718000000.0. The EBITDA in the recently reported quarter was $1039000000.0 and diluted EPS was $0.32.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BSX since 15 analysts follow the stock currently. There are 13 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BSX analysts setting a high price target of 119.0 and a low target of 83.0, the average target price over the next 12 months is 102.71031. Based on these targets, BSX could surge 16.26% to reach the target high and fall by -18.91% to reach the target low. Reaching the average price target will result in a growth of 0.34% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.47558 being high and $2.45554 being low. For BSX, this leads to a yearly average estimate of $2.46556. Based on analyst estimates, the high estimate for the next quarter is $0.68 and the low estimate is $0.6. The average estimate for the next quarter is thus $0.65.
#####
#####
#####
#####
